Oncologist. Researcher. Corporate CMO and GM of ECD at Natera. Helping bring ctDNA testing to patients. Opinions my own
Palo Alto, CA
Joined April 2009
- Tweets118
- Following147
- Followers295
- Likes166
Alexey Aleshin retweeted
Join this upcoming webinar to learn how circulating tumor DNA (ctDNA) testing can help detect colorectal cancer recurrence earlier, monitor treatment response, and guide next steps in cancer care.
💙 Patients and caregivers are invited to submit questions in advance for presenter Dr. John Strickler, and he will answer as many as possible during the live Q&A.
📅Tuesday, March 17
🕗 5 PM PT | 8 PM ET
📍Register: ow.ly/TNCS50YoJa5
Alexey Aleshin retweeted
Join our upcoming webinar, From data to decision: The emerging role of ctDNA-MRD in lymphoma patient care, with David Kurtz, MD, PhD and Jake Chabon, PhD, on Thursday, March 5.
Discover how seeing beyond traditional imaging allows for a more nuanced, real-time understanding of patient response and disease burden.
Topics include:
• The Science of Detection
• Clinical Utility & Outcomes
• The Future Landscape
• Review of Lymphoma Patient Cases
Register today: ow.ly/vrN950Yj2tr
@JakeChabon
Alexey Aleshin retweeted
Presented at #ESMO25:
In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial results: nej.md/3WIRtEg
@myESMO
ALT Panel A: A graph of investigator-assessed disease-free survival among all patients with ctDNA-positive status who underwent randomization (primary end point). Panel B: A graph of overall survival in the same population (secondary end point).
Alexey Aleshin retweeted
VIDEO: Celecoxib / Celebrex & ctDNA in Stage III Colon Cancer findings from the CALGB Alliance / SWOG 80702 at ASCO GI @jonathan_nowak @ASCO #GI25 @BrighamWomens @BWHPath @DanaFarber @harvardmed @OncoAlert #Celecoxib #ctDNA #ColonCancer #ASCOGI2025 #CancerResearch #Oncology #PersonalizedMedicine #TumorMicroenvironment #CancerTreatment #MedicalResearch #JonathanNowakMD #BrighamAndWomensHospital
Alexey Aleshin retweeted
ctDNA Status Is Prognostic for DFS With Celecoxib in Stage III Resected Colon Cancer @jonathan_nowak @BrighamWomens @BWHPath @DanaFarber @harvardmed @ASCO #GI25 #crcsm #medtwitter #oncology onclive.com/view/ctdna-statu…
Alexey Aleshin retweeted
Patients with colon cancer with positive ctDNA tests often face tougher outcomes. Research by @DanaFarber & @BrighamWomens presented at #ASCOGI shows that treatment with a non-steroidal anti-inflammatory drug significantly boosts disease-free survival.
➡️ bit.ly/4g9zO01
Alexey Aleshin retweeted
We're excited to share that we have passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting #Natera’s technology in the scientific literature. 👏natera.com/company/news/nate…
Alexey Aleshin retweeted
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial
buff.ly/3O6YHxr
@tompowles1 @ZoeJuneAssaf @PGrivasMDPhD @aaleshin @OncoBellmunt @SanjMariathasan
Alexey Aleshin retweeted
We are pleased to announced that @Merck will utilize Natera’s real-world database of de-identified clinical and genomic data from more than 100,000 early- and late-stage cancer patients who have been tested with #Signatera to advance oncology research.
ow.ly/rCnI50Q7v0S
Alexey Aleshin retweeted
ctDNA testing has shown great promise in solid tumors for monitoring disease progression and detecting relapse in real time. This article reports on the use of #ctDNA testing specific to anal squamous cell carcinoma. doi.org/10.1093/oncolo/oyac2…
Alexey Aleshin retweeted
In the observational arm of the CIRCULATE-Japan study, among patients with stage II-IV #ColorectalCancer, those with the presence of circulating #tumorDNA post-tumor resection have a high recurrence risk & are likely to benefit from adjuvant #chemotherapy
nature.com/articles/s41591-0…
New GALAXY data published by Drs Kotani and Yoshino in #Nature Medicine. (1) ctDNA is most prognostic factor for DFS (2) ACT in ctDNA (+) pts associated w/ improved DFS, but NOT in ctDNA (-) (3) ctDNA dynamics -> tx efficacy #ctDNA #CRC #Natera #Signatera
nature.com/articles/s41591-0…
Additional findings: (1) more than >50% of markers selected where unique to just 1 patient-> tumor informed + personalized assays (2) Higher MRD levels associated with lower probability of clearance -> importance of quantification (3) Presurgical ctDNA detection not prognostic
